| Next 10 |
DCPH News and Press, Deciphera Pharmaceuticals Inc.
-
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2...
-
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
-
Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...
-
-QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study- -NDA Approved 3 Months Prior to Action Date Under FDA’s Real Time Oncology Review (RTOR)- -Deciphera to Host Conference Call Today at 5:0...
-
The FDA approves Deciphera Pharmaceuticals' ( DCPH +6.7% ) ripretinib, branded as Qinlock, for the fourth-line treatment of gastrointestinal stromal tumor (GIST). More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
-
Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...
-
Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...
-
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q1 2020 Results - Earnings Call Transcript
Deciphera Pharmaceuticals Inc (DCPH) Q1 2020 Earnings Conference Call May 5, 2020 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commer...
-
Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2020 Earnings Call May 5, 2020 , 4:30 p.m. ET Operator Continue reading
-
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q1 GAAP EPS of -$1.36 misses by $0.05 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Stock Information
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
MENU
DCPH
DCPH Quote
DCPH Short
DCPH News
DCPH Articles
DCPH Message Board
Get DCPH Alerts
News, Short Squeeze, Breakout and More Instantly...
RECENT DCPH NEWS
-
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2...
-
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
-
Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...
